Observational studyThe Journal of clinical endocrinology and metabolism2020
Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-based Study.
Observational study in The Journal of clinical endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- 2024 Royal Australian College of General Practitioners and Healthy Bones Australia guideline for osteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age.The Medical journal of Australia · 2025Guideline
- Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians.Annals of internal medicine · 2023Guideline
- Impact of clinical pharmacist-led interventions on denosumab adherence.Archives of osteoporosis · 2026Article
- 5-methoxyresorcinol mitigates postmenopausal osteoporosis through regulation of the PI3K-AKT-GSK3β signaling pathway and ROS homeostasis.Frontiers in pharmacology · 2026Article
- Expert insight into the education of healthcare professionals on medication adherence.British journal of clinical pharmacology · 2025Article
- Treatment of Osteoporosis in Patients with Chronic Kidney Disease.Current osteoporosis reports · 2025Review
- Adherence of denosumab treatment for low bone mineral density in Japanese people living with HIV: a retrospective observational study.Journal of pharmaceutical health care and sciences · 2023Article
- Impact of the COVID-19 Pandemic on Adherence to Denosumab Therapy: A Single Center Study.Asian spine journal · 2023Article
- Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023Article
- Automatic Estimation of the Most Likely Drug Combination in Electronic Health Records Using the Smooth Algorithm: Development and Validation Study.JMIR medical informatics · 2022Article
- A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis.Head & face medicine · 2021Article
- Persistence with oral bisphosphonates and denosumab among older adults in primary care in Ireland.Archives of osteoporosis · 2021Article
- Should denosumab treatment for osteoporosis be continued indefinitely?Therapeutic advances in endocrinology and metabolism · 2021Review
- Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-based Study.The Journal of clinical endocrinology and metabolism · 2020Observational
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
contextDiscontinuation of denosumab leads to a rapid reversal of its therapeutic effect. However, there are no data regarding how unintended delays or missed injections of denosumab impact bone mineral density (BMD) response.
objectiveWe examined the association of delays in injections of denosumab with BMD change.
designWe used electronic medical records from two academic hospitals from 2010 to 2017.
participantsPatients older than 45 years of age and used at least 2 doses of 60 mg denosumab. Denosumab adherence was evaluated by the medication coverage ratio (MCR). Good adherence corresponds to a dosing interval ≤7 months (defined by MCR ≥93%), moderate adherence corresponds to an interval of 7 to 10 months (MCR 75%-93%), and poor adherence corresponds to an interval ≥10 months (MCR ≤75%). OUTCOME MEASURES: Annualized percent BMD change from baseline at the lumbar spine, total hip, and femoral neck.
resultsWe identified 938 denosumab injections among 151 patients; the mean (SD) age was 69 (10) years, and 95% were female. Patients with good adherence had an annualized BMD increase of 3.9% at the lumbar spine, compared with patients with moderate (3.0%) or poor adherence (1.4%, P for trend .002). Patients with good adherence had an annualized BMD increase of 2.1% at the total hip, compared with patients with moderate (1.3%) or poor adherence (0.6%, P for trend .002).
conclusionsA longer interval between denosumab injections is associated with suboptimal BMD response at both spine and total hip. Strategies to improve the timely administration of denosumab in real-world settings are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.